title: [Does administration of fibrin glue prevent development of lymphoceles after radical lymphadenectomy?].
abstract: Surgical approaches to the groin and axilla, almost radical lymph node dissections (RLND) are followed frequently by lymphocysts. In a prospective randomized study of 30 inguinal or axillary RLND we used at half of the cases 1 ml of the two-component fibrin glue (Tissucol), applied as a spray to seal the wound at the end of the operation. At 27 patients not only a prophylactic RLND but a selective hyperthermic cytostatic perfusion of the extremity was performed because of a locally advanced malignant tumor. There was no difference between the two groups of patients in age, diagnosis, surgical technique, and follow-up. In two cases of the fibrin glue (FG)-group and in 4 cases of the control group a second intervention because of a local wound healing problem had to be performed. The mean amount of postoperative drainage fluid was 1065 +/- 822 ml at the FG-group and 1332 +/- 1093 ml at the control group. Also postoperative drainage time (9 vs. 12 days) and postoperative hospital stay (18 vs. 22 days) were shorter at the FG-group, however, without statistical significance. 11 of 14 patients of the FG-group and 10 of 14 patients of the control group had normal scars after lymphadenectomy without signs of lymphocysts at the clinical follow-up. At our high risk patients (very high amount of postoperative drainage fluid in comparison to other series) prophylactic fibrin glue sealing after RLND could not prevent lymphocysts and lymphatic fistulae.
authors.affiliation: Universitätsklinik für Thorax-, Herz- und Gefässchirurgie, Inselspital, Bern.
authors.forename: M
authors.initials: M
authors.lastname: Furrer
authors.forename: R
authors.initials: R
authors.lastname: Inderbitzi
authors.forename: B
authors.initials: B
authors.lastname: Nachbur
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001365:Axilla / Q000601:surgery; D004322:Drainage; D005121:Extremities / Q000601:surgery; D005260:Female; D015718:Fibrin Tissue Adhesive / Q000008:administration & dosage*; D005500:Follow-Up Studies; D006801:Humans; D007264:Inguinal Canal / Q000601:surgery; D008197:Lymph Node Excision / Q000379:methods*; D008198:Lymph Nodes / Q000473:pathology; D008210:Lymphocele / Q000473:pathology / Q000517:prevention & control*; D008297:Male; D008545:Melanoma / Q000473:pathology / Q000601:surgery*; D008875:Middle Aged; D011183:Postoperative Complications / Q000473:pathology / Q000517:prevention & control*; D011446:Prospective Studies; D012878:Skin Neoplasms / Q000473:pathology / Q000601:surgery*; D014945:Wound Healing / Q000187:drug effects
chemical_list: D015718:Fibrin Tissue Adhesive
vernacular_title: Verhindert die Applikation von Fibrinkleber die Entwicklung von Lymphocelen nach radikalen Lymphadenektomien?